This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Mineralys Therapeutics’s 8K filing here.
Mineralys Therapeutics Company Profile
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.
Recommended Stories
- Five stocks we like better than Mineralys Therapeutics
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Warren Buffett Bets on the Digital Economy With New VeriSign Buy
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Discover 2 Under-the-Radar Aerospace Stocks Set for 2025 Growth
- What is the Hang Seng index?
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
